scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Companyâ€™s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companyâ€™s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

Employees

163

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq 23:00:00 06/10/2025 +03			5-day change	1st Jan Change
5.670 ^USD	-.--%		-.--%	-

07/10/25	MannKind Corporation completed the acquisition of scPharmaceuticals Inc..	CI
07/10/25	MannKind Completes Acquisition of scPharmaceuticals	MT

Market Cap	305M 262M 246M 225M 423M 29B 426M 2.92B 1.14B 14.71B 1.14B 1.12B 48.7B	P/E 2027 *	-	P/E 2028 *	-
Enterprise Value	281M 242M 227M 207M 389M 26.72B 392M 2.69B 1.05B 13.55B 1.05B 1.03B 44.87B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	98.42%	Yield 2027 *	-	Yield 2028 *	-

07/10/25	MannKind Corporation completed the acquisition of scPharmaceuticals Inc..	CI
07/10/25	MannKind Completes Acquisition of scPharmaceuticals	MT
07/10/25	MannKind completes acquisition of ScPharmaceuticals, accelerating revenue growth in cardiometabolic care	RE
07/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from S&P Global BMI Index	CI
07/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from S&P TMI Index	CI
07/10/25	ScPharmaceuticals Inc.(NasdaqGM:SCPH) dropped from NASDAQ Composite Index	CI
06/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from NASDAQ Biotechnology Index	CI
06/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell Small Cap Comp Growth Benchmark	CI
06/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell Microcap Growth Benchmark Index	CI
06/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 3000E Growth Benchmark	CI
06/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 3000 Growth Benchmark	CI
06/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 2500 Growth Benchmark	CI
06/10/25	ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 2000 Growth Benchmark	CI

29/08/25	HC Wainwright Downgrades scPharmaceuticals to Neutral From Buy	MT
26/08/25	Maxim Downgrades scPharmaceuticals to Hold From Buy	MT
26/08/25	Craig-Hallum Downgrades scPharmaceuticals to Hold From Buy, Adjusts Price Target to $6 From $12	MT
20/03/25	Maxim Adjusts Price Target on scPharmaceuticals to $12 From $20, Keeps Buy Rating	MT
07/09/23	Craig-Hallum Starts scPharmaceuticals at Buy With $20 Price Target	MT

scPharmaceuticals Inc. Stock

Stocks

SCPH

US8106481059

Pharmaceuticals

Valuation : scPharmaceuticals Inc.

Chart: scPharmaceuticals Inc.

Latest news : scPharmaceuticals Inc.

Last Transcript : scPharmaceuticals Inc.

Analysts' recommendations : scPharmaceuticals Inc.

Press Releases : scPharmaceuticals Inc.

News in other languages : scPharmaceuticals Inc.

Price Extremes

Managers and Directors : scPharmaceuticals Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

16/09/25	SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH	BU
27/08/25	SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH	BU
25/08/25	MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases	AQ
14/08/25	ScPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111	AQ
07/08/25	ScPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update	AQ

1 year	5.5	5.7
3 years	1.94	7.74
5 years	1.94	12.75
10 years	1.94	18.17

Manager	Title	Age	Since
Michael Castagna CEO	Chief Executive Officer	49	07/10/2025
Christopher Prentiss DFI	Director of Finance/CFO	50	07/10/2025
David Thomson SEC	Corporate Secretary	59	07/10/2025

Director	Title	Age	Since
Michael Castagna BRD	Director/Board Member	49	07/10/2025
David Thomson BRD	Director/Board Member	59	07/10/2025
Christopher Prentiss BRD	Director/Board Member	50	07/10/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/7/25 A	Frederick Hudson	Issuer sale	Director	72,174	0.1442%
10/7/25 A	Minnie Baylor-Henry	Issuer sale	Director	84,422	0.1687%
10/7/25 A	Mette Agger	Issuer sale	Director	49,750	0.0994%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCPHARMACEUTICALS INC.	-.--%	-.--%	+3.09%	-26.65%	305M
ELI LILLY AND COMPANY	-1.24%	-6.85%	+57.99%	+109.59%	1,047B
JOHNSON & JOHNSON	-0.74%	-2.44%	+49.60%	+64.75%	646B
ABBVIE INC.	+0.43%	-2.43%	+21.79%	+75.62%	451B
ROCHE HOLDING AG	-1.64%	-4.75%	+35.59%	+35.54%	355B
NOVARTIS AG	-0.39%	-2.76%	+21.39%	+38.01%	291B
ASTRAZENECA PLC	-1.19%	-2.21%	+1.53%	+11.51%	252B
AMGEN INC.	-0.57%	-3.06%	+49.96%	+67.85%	234B
NOVO NORDISK A/S	-1.05%	-2.29%	-19.91%	-54.10%	203B
GILEAD SCIENCES, INC.	+0.54%	-0.21%	+29.92%	+91.46%	181B
Average	-0.70%	-2.41%	+25.09%	+41.36%	365.96B
Weighted average by Cap.	-0.89%	-3.46%	+36.85%	+65.22%

	2027 *	2028 *
Net sales	-	-
Net income	-	-
Net Debt	-	-